Supplementary Figure S9 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure 9. Median overall survival (A-C) and progression-free survival (B-D) according to MAPK status in NI (A-B) and N-CT (C-D) treatment arm. MAPK1/3 WT (yellow line; n = 26/31) vs MAPK1–3 altered (blue line; n = 48/32). OS: Overall survival; PFS: progression-free survival; WT: wild-type.